



## **KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)**

September 2, 2022

CAMBRIDGE, Mass & SALISBURY, England--(BUSINESS WIRE)--Sep. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on September 1, 2022 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of \$16.83 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

### **About KalVista Pharmaceuticals, Inc.**

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information, please visit [www.kalvista.com](http://www.kalvista.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220902005066/en/): <https://www.businesswire.com/news/home/20220902005066/en/>

### **KalVista Pharmaceuticals, Inc.**

Jarrold Aldom  
Vice President, Corporate Communications  
(201) 705-0254  
[jarrod.aldom@kalvista.com](mailto:jarrod.aldom@kalvista.com)

Source: KalVista Pharmaceuticals, Inc.